Vital Sines International Inc.

Financé avec succès!

167 273 $
Collectés sur un objectif de 100 000 $ 167%
22
investisseurs
Campagne terminée
Aperçu

The VitalSines team has an expertise in optical sensors and bio-signal analysis. Their passion is creating products that help people live longer and healthier lives through health technology. Their first product iHeart was developed as a tool to help people monitor Aortic Stiffness easily and cost effectively. Aortic Stiffness is a scientifically proven heart, brain, and internal health metric directly related to risk of death from all causes, but was previously only measured by a $25,000 medical device. The team developed an easy to use and much less expensive way for consumers and health and wellness professionals to measure Aortic Stiffness in just 30-seconds. iHeart is now being used in over 800 cities around the world and the VitalSines team is dedicated to bringing iHeart technology to everyone possible to help people live longer and healthier lives. VitalSines is a company with impressive IP and an exciting pipeline that will change the way internal health is measured and viewed, all over the world.

Note: iHeart is NOT a medical device, it is intended to be used as a health and wellness educational device only and not as a diagnostic tool. 

Product or Service 

iHeart is a fingertip device and mobile app that determines a user’s Internal Age in 30-seconds by measuring a scientifically proven heart, brain, and internal health metric called Aortic Stiffness by measuring Aortic Pulse Wave Velocity through the pulse in the finger.

Previous to iHeart the only method to attain this informational rich health metric was via a $25,000 medical device that required a skilled operator. Dr. Jess Goodman, President and Founder of VitalSines, studied Aortic Pulse Wave Velocity and the effects of positive lifestyle choices on this metric for over 20 years. Dr. Goodman set out to develop an easy to use and cost effective tool that consumers and health and wellness professionals could use to objectively see improvements to internal health after incorporating positive lifestyle choices by measuring Aortic Stiffness.

The iHeart device has two separate applications, one that is free for life for consumer use, and another that is a pay per month application developed for use by health and wellness professionals all over the world. This application shows their clients objective evidence that their health and wellness services are improving their client’s health.

The VitalSines team has an expertise in health and wellness, optical sensors, and bio-signal analysis. iHeart is the first product in a very exciting pipeline from this passionate and driven team.

First and foremost the VitalSines team wants to help people live longer and healthier lives all over the world.

 

Market 

The health and wellness technology market is booming with activity trackers and calorie counters, but iHeart is something revolutionary. iHeart shows objective evidence that positive lifestyle choices are actually making drastic improvements to internal health.

The market for the iHeart consumer are women and men ages 45-65 all over the world.

The market for iHeart PRO are health and wellness professionals of all ages all over the world. These professionals, as well as groups that are listed below:

  • Personal Trainers
  • Nutritionists
  • Health Coaches
  • Yoga Instructors
  • Naturopaths
  • Chiropractors
  • Physiotherapists
  • Kinesiologists
  • Corporate Wellness Companies
  • Large Gyms and Fitness Studios
  • Weight Loss Centres (curves, weight watchers, etc)
  • Rehabilitation Facilities
  • Spas
  • Anti Aging Centres 


Revenue Model 

We sell the iHeart hardware for $195 USD and have a landed cost of $33 USD, which is $162 in profit for each device sold. We market worldwide and have distributors who sell online and in retail locations.

 The PRO software is a subscription model which users pay per month starting at $9.99/USD. There are 1,3,6, and 12 month subscriptions.


Use of Proceeds

We will be using the proceeds from this raise for the following:


Exit Strategy 

VitalSines plans to grow dramatically over the next several years and will be reinvesting its operating cash flow in to research and development and the continued growth of the company. Once operations have reached an optimal level, management will consider the best exit strategy for its shareholders. This may include a strategic merger or acquisition, or an initial public offering.

 

Investment Highlights

  • Capital raised in previous rounds: $50,000
  • Current Target raise: $250,000
  • Maximum current raise: $500,000
  • Minimum current raise: $100,000
  • Pre-money valuation: $3,506,135.66
  • Equity offered (target raise): 7%
  • Equity offered (maximum raise): 12%
  • Offering (unit) type: Common Shares (with Voting Trust Agreement)
  • Price per unit: $0.34
Rencontrer l'équipe
Sarah Goodman
CEO
Dr. Jess Goodman
President & Founder
Benoit Lewden
CTO
Mises à jour

Kara Zucker

mars 07, 2017

iHeart

Fit on the inside: Dragons liked iHeart app for its immediate read of aortic health

  • Financial Post: Entrepreneur

  • Author: Mary Teresa Bitti

  • Published Feb 22, 2017

Investisseurs
22 total, 9 anonyme
Documents
General Risks
En accédant à ce site, vous acceptez les conditions générales et Politiques de confidentialitéde FrontFundr. FrontFundr distribue des titres du marché dispensé à des personnes admissibles au sens de la Norme canadienne 45-106 ainsi que les dispenses de prospectus et d'inscription et les dispenses de financement anticipé, y compris le Règlement 45-108 sur le financement anticipé et l'Avis 45-316 des ACVM sur le financement anticipé de démarrage et les dispenses de prospectus.
En tant que courtier sur le marché dispensé, Silver Maple peut négocier et souscrire des titres du marché dispensé.. Exempt market securities are risky investments and you could lose all the money you invest in such securities.
In general, investment products sold in the exempt market are considered high risk because:
  1. They are not covered by deposit or investor protection insurance;
  2. Regulators do not review offering memoranda for completeness;
  3. Private issuers are not subject to the same ongoing disclosure obligations as reporting issuers;
  4. Private issuers may inadvertently, or advertently, refrain from providing an investor or a registered dealer, all the information required to make an informed investment decision.
  5. Many exempt products are not as liquid as publicly-traded securities and you may be restricted in your ability to sell or transfer these securities; and
  6. Exempt products are often subject to a greater degree of “key person” risk than more widely held securities.
  7. There can be no assurances that an investment will maintain its net acquisition value or produce any projected income or capital return. Investment values change frequently and past performances may not be repeated.
  8. Using borrowed money to finance the purchase of securities involves greater risk than a purchase using cash resources. If you borrow money to purchase securities, your responsibility to repay the loan and pay interest as required by its terms remains the same even if the value of the securities purchased declines. See “use of borrowed funds”.
The risks highlighted above are not conclusive. Risk disclosures specific for each offering are reviewed by SMV and are presented within an issuer’s profile page on the platform and within the offering memorandum or other offering documents for the issuance. Offering documents and the risks associated with the securities of an issuer contained therein should be reviewed thoroughly by an investor or an investor’s professional advisors before making an investment.
This web site is for general information only and is not intended to provide personalized advice, including investment, financial, legal, accounting or tax advice. FrontFundr will assess your suitability to invest in the products offered on its platform.
Contactez-nous
Site Web
Courriel